Human papillomavirus infection

SQZ Biotechnologies and Collaborators Publish Technology Review on SQZ® APCs and Effective CD8 T Cell Activation

Retrieved on: 
Tuesday, July 12, 2022
Research, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Cell engineering, Centers for Disease Control and Prevention timeline, Vulva, EBV, Autoimmunity, Annual report, DLT, Patient, MD, TP53, Private Securities Litigation Reform Act, Â, European Society of Gene and Cell Therapy, Woman, Cancer, Infection, U.S. Securities and Exchange Commission, Confidentiality, PD-1, International Journal of Cancer, Risk, Cell, Degenerative disease, Virus, E7, APC, CDC, Human papillomavirus infection, NK, MHC, Immune tolerance, Safety, Tumor microenvironment, Center, Penis, COVID-19, Therapy, Neoplasm, FDA, Canadian International Council, E6, NYSE, CD8, Man, Comparison, Oncology, KRAS, Review, Congress, Monocyte, Research, SQZ, HPV, Publication, Vaccine, Medical imaging, Pharmaceutical industry, Technology

Published in ESMOs Immuno-Oncology and Technology (IOTECH) journal, the review further explores the advantages of the companys Cell Squeeze technology in cell engineering and manufacturing as well as potential opportunities to develop additional clinical candidates with enhanced capabilities.

Key Points: 
  • Published in ESMOs Immuno-Oncology and Technology (IOTECH) journal, the review further explores the advantages of the companys Cell Squeeze technology in cell engineering and manufacturing as well as potential opportunities to develop additional clinical candidates with enhanced capabilities.
  • We look forward to potentially building on these early results through combination with various immunomodulatory drugs, such as checkpoint inhibitors.
  • SQZ has three ongoing Phase 1/2 clinical trials aiming to drive CD8 T cell responses against HPV16+ solid tumors.
  • SQZ Biotechnologies is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies to benefit patients with cancer, autoimmune and infectious diseases.

OmniPathology Announces the Launch of its Oropharyngeal HPV PCR Test

Retrieved on: 
Tuesday, July 12, 2022
Infection, Male, Smoking, Man, Centers for Disease Control and Prevention timeline, Human papillomavirus infection, Science, ENT, Colon, Risk, Patient, CEO, Center, Ear, Risk factor, GLOBE, Physician, STI, LDT, Nose, Oral, Pathology, Health, GYN, Woman, Immune system, Esophageal cancer, Cancer, HPV, CDC, Dentist, Vaccine

The Oral HPV Test is a lab-developed test (LDT) performed on a Roche cobas 6800 and 8800 high-throughput platforms.

Key Points: 
  • The Oral HPV Test is a lab-developed test (LDT) performed on a Roche cobas 6800 and 8800 high-throughput platforms.
  • The Oral HPV Test detects 14 high-risk strains of HPV.
  • Launching this oropharyngeal HPV test is an exciting milestone for OmniPathology, especially since this is an underserved area for diagnostic testing.
  • For more information about the new Oral HPV Test, please contact OmniPathology at http://omnipathology.com/closer-look .

Europe Cervical Cancer Screening Market Report 2022: Sector Expected to be Valued at US$ 10.7 Billion in 2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 7, 2022
Medical Devices, Women, Consumer, Health, Oncology, Cell, Patient, HPV, Research, Cervical cancer, Human papillomavirus infection, COVID-19, Country, Population, US, Awareness, Woman, United Kingdom, CAGR, Non-functional testing, Uterus, Cervical, Health, Incidence, Cancer, California Healthcare Institute, Birth control, Vaccine, Growth

Europe Cervical Cancer Screening Market is expected to be valued at US$ 10.7 Billion in 2027.

Key Points: 
  • Europe Cervical Cancer Screening Market is expected to be valued at US$ 10.7 Billion in 2027.
  • As a result, cervical cancer screening is an essential aspect of a woman's routine health and can aid in cervical cancer prevention.
  • Europe Cervical Cancer Screening Market is estimated to expand with a CAGR of 3.3% during 2021-2027:
    The European Cervical Cancer Screening Market has grown in recent years due to an increase in the number of patients diagnosed with cervical cancer and increased awareness about cervical cancer screening programs.
  • By Country - Europe Cervical Cancer Test Market & Population Share Analysis:
    The Europe Cervical Cancer Test Market & Population Share Analysis has been done for the United Kingdom, France, Germany, Italy, Spain, Sweden, Switzerland, Norway, and the Netherlands in our report.

At 9.8%, Cancer Vaccines Market is Expected to Reach USD 12.64 Billion in 2027, Says Brandessence Market Research

Retrieved on: 
Tuesday, June 28, 2022
Minister of Finance (Malaysia), Patient, USD, HPV, Adoption, Cervical cancer, Growth, Cancer, Prostate cancer, Prevalence, Awareness, Human papillomavirus infection, Investment, CAGR, Traction, Prostate, Lung, Merck & Co., Tobacco, Vaccine, Government, WHO, Pharmaceutical industry, Technology, Application

LONDON, June 28, 2022 /PRNewswire/ -- Cancer Vaccines Market was worth of USD 4.93 Billion in 2020 and it is expected to reach USD 12.64 Billion by the end of 2027 with a CAGR of 9.8% during the Forecast Period.

Key Points: 
  • LONDON, June 28, 2022 /PRNewswire/ -- Cancer Vaccines Market was worth of USD 4.93 Billion in 2020 and it is expected to reach USD 12.64 Billion by the end of 2027 with a CAGR of 9.8% during the Forecast Period.
  • Cancer Vaccines Market Size, Share & Trends Analysis Report By Type (Therapeutic Cancer Vaccine, Preventive Cancer Vaccine, Others) By Application (Prostate Cancer, Cervical Cancer, Others) By Technology (Whole-Cell Cancer Vaccine, DNA Cancer Vaccine, Recombinant Cancer Vaccine, Others) Based On Region, And Segment Forecasts, 2022 2028
    The global cancer vaccines market is seen growing in stature in the past few years and is expected to continue this trend further in the coming years.
  • The preventive cancer vaccines and the therapeutic cancer vaccines are a couple of cancer vaccines which are used in a healthy person to prevent cancer.
  • The Therapeutic cancer vaccines are used in the patients for strengthening their immune response to fight against this deadly disease.

Kovina Therapeutics Receives National Cancer Institute Grant to Advance Human Papillomavirus Cancer Treatment

Retrieved on: 
Monday, June 27, 2022
Oncology, Health, Infectious Diseases, Research, Science, Pharmaceutical, Biotechnology, Transfer, Patient, CEO, Biotechnology, SBIR, HPV, NCI, Research, Mentorship, CSO, Small Business Innovation Research, Cancer, Therapy, Human papillomavirus infection, National Cancer Institute, Technology, STTR, Infection, Pharmaceutical industry, Vaccine

Kovina Therapeutics Inc. announced receipt of a Fast-Track Small Business Technology Transfer (STTR) grant from the National Cancer Institute/NIH.

Key Points: 
  • Kovina Therapeutics Inc. announced receipt of a Fast-Track Small Business Technology Transfer (STTR) grant from the National Cancer Institute/NIH.
  • We are excited to receive NCI funding to support Kovinas development of therapeutic treatments for Human Papillomavirus (HPV) related cancers, said Kristin Sherman, CEO of Kovina Therapeutics.
  • We are pleased Kovinas research proposal successfully competed in NCIs rigorous merit-based review process, said Dr. Elliot Androphy, CSO of Kovina Therapeutics.
  • Kovina Therapeutics is a biotechnology company developing first-in-class antiviral therapies to treat cancers and pre-malignant infections caused by Human Papillomavirus (HPV).

Researchers Find That a Japanese Medicinal Mushroom Extract Can Help the Body Clear Persistent HPV Infections

Retrieved on: 
Wednesday, June 22, 2022
Name, Association, FACOG, Reproductive Sciences, AHCC, Gynaecology, Human papillomavirus infection, Infection, Head and neck cancer, Polysaccharide, Cell wall, Cancer, Cervical cancer, Research, Frontiers, Man, McGovern Medical School, Baylor University, Department, MEDLINE, HPV, DNA, Vaccination, MD, FACS, Immune system, UCLA, Patient, Dan, Assistant, Baylor College of Medicine, Department of Obstetrics and Gynecology (Massachusetts General Hospital), Malnutrition, Woman, Life, Risk, Dietary supplement, Vaccine, Obstetrics

NEW YORK, June 22, 2022 /PRNewswire/ -- According to a paper published in Frontiers in Oncology, daily use of a unique mushroom extract AHCC® supported the immune system in clearing HPV infections in two-thirds of study participants after six months of supplementation.

Key Points: 
  • The study focused on women with a greater than two-year history of persistent high-risk HPV.
  • Most healthy individuals with optimally functioning immune systems can clear HPV infections on their own within two years.
  • While HPV vaccination represents the best deterrent for cancers associated with high-risk HPV infection, we need treatment options for those patients who do have persistent high-risk HPV.
  • The data in this study will help guide future interventions for persistent high-risk HPV infection,"says Dr.Joshua G. Cohen, MD, FACOG, FACS of UCLA.

HOOKIPA announces positive Phase 1 data and Phase 2 plans for HB-200 program for the treatment of advanced head and neck cancers at ASCO

Retrieved on: 
Sunday, June 5, 2022
Immunotherapy, Penile cancer, Head, HNSCC, Cell, Society, Lung, RECIST, HPV16, Food, Progression-free survival, Vulvar cancer, Standard of care, Human papillomavirus infection, Degenerative disease, Cancer, ASCO, Annual general meeting, Prostate cancer, CD8, Pembrolizumab, American Society of Clinical Oncology, Prostate, Therapy, GLOBE, Patient, Fast track (FDA), HBV, Technology, Arenavirus, E7, DNA, HPV, NASDAQ, NEW, Clinical trial, Population, HIV, Neck, Gilead, Protein, KRAS, University, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MD Anderson Cancer Center, Person, Safety, Lymphocytic choriomeningitis, Vaccine, Pharmaceutical industry

The data were presented in a poster presentation (abstract #2517) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

Key Points: 
  • The data were presented in a poster presentation (abstract #2517) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • These results help focus our efforts as we move HB-202/HB-201 at the recommended Phase 2 dose into the Phase 2 portion of the trial.
  • Sixty-eight patients with advanced HPV16+ cancers were treated in the Phase 1 trial as of March 31, 2022.
  • Fifty-four patients had advanced HPV16+ head and neck cancers with a median of three prior therapies (range of 1-11), including a checkpoint inhibitor regimen in 50 of the 54.

Microbix Presenting Test Validation Methods at AACC

Retrieved on: 
Friday, June 3, 2022
American Association for Clinical Chemistry, Goal, Company, ISO 9001, OTCQX, TGA, News, CE, Organization, American Association, Method, FDA, GLOBE, Health Canada, U.S. FDA, Health, COVID-19, TSX, Medical device, Stock, HPV, Poster, Severe acute respiratory syndrome coronavirus 2, QAP (Colombia), Association, AACC, Engineering, Antigen, FH, Human papillomavirus infection, Vaccine, Online shopping

Microbix is attending this AACC conference to present about these important aspects of infectious disease testing, alongside leaders in the global medical diagnostics industry.

Key Points: 
  • Microbix is attending this AACC conference to present about these important aspects of infectious disease testing, alongside leaders in the global medical diagnostics industry.
  • Its poster presentation is titled Simulated Swab Specimens for Whole Workflow Quality Control of SARS-CoV-2 Molecular Diagnostic Testing.
  • Microbix creates proprietary biological products for human health, with over 100 skilled employees and sales approaching C$ 2.0 million per month.
  • Microbix is ISO 9001 and 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides CE marked products.

HOOKIPA to Present Complete HB-200 Phase 1 Results and Recommended Phase 2 Dose for HB-202/HB-201 for the Treatment of Advanced HPV16+ Cancers at ASCO

Retrieved on: 
Thursday, May 26, 2022
Cancer, DNA, Degenerative disease, Immunotherapy, Annual general meeting, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, HBV, Food, Vulvar cancer, NEW, KRAS, Progression-free survival, HPV16, Patient, Science, Prostate, Gilead, NASDAQ, PD-1, RECIST, Fast track (FDA), CD8, Clinical trial, Society, Penile cancer, American Society of Clinical Oncology, Cell, HNSCC, Pembrolizumab, Arenavirus, Prostate cancer, Neck, Technology, Safety, Biomarker, ASCO, Standard of care, Lymphocytic choriomeningitis, Head, Lung, Human papillomavirus infection, Protein, HIV, E7, HPV, GLOBE, Medical imaging, Pharmaceutical industry, Online shopping, Vaccine

We look forward to sharing the full Phase 1 data results on our HB-200 program at ASCO.

Key Points: 
  • We look forward to sharing the full Phase 1 data results on our HB-200 program at ASCO.
  • The final analysis shows that HB-201 and 2-vector HB-202/HB-201 were generally well tolerated and showed anti-tumor activity in these difficult-to-treat patients.
  • The primary endpoint of Phase 1 is a recommended Phase 2 dose.
  • In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead.

BD Launches Fully Automated, High-Throughput Infectious Disease Molecular Diagnostic Platform in the U.S.

Retrieved on: 
Thursday, May 12, 2022
Risk, DNA, STI, Disease, Company, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Urine, CT, BD, Patient, Solution, Health, Trichomonas, CE, COVID-19, Collection, Becton, FDA, Efficiency, GC, Female, Trichomonas vaginalis, Pregnancy, Neisseria gonorrhoeae, Safety, Organization, MX, BDX, Human papillomavirus infection, Therapy, LinkedIn, Twitter, HIV, Becton, Dickinson and Company headquarters, GX, Male, Laboratory, NYSE, Chlamydia trachomatis, HPV, Pharmaceutical industry, Medical device, Chlamydia

FRANKLIN LAKES, N.J., May 12, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. launch of its new, fully automated, high-throughput infectious disease molecular diagnostics platform.

Key Points: 
  • FRANKLIN LAKES, N.J., May 12, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. launch of its new, fully automated, high-throughput infectious disease molecular diagnostics platform.
  • With 510(k) clearance from the U.S. Food and Drug Administration (FDA), the new BD COR MX instrument is a new analytic instrument option for the BD COR System.
  • The BD COR MX/PX System integrates and automates the complete molecular laboratory workflow, from sample processing to diagnostic test result for large, high-throughput labs.
  • The BD COR System is fully automated, modular, and scalable instrument, designed to address multiple needs within laboratories to handle expanding molecular testing volumes.